Related Experiment Video
Updated: Jun 18, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple-negative breast cancer--current status and future directions
O Gluz1, C Liedtke, N Gottschalk
1Westdeutsche Studiengruppe GmbH, Mönchengladbach, Germany.
Summary
Triple-negative breast cancer (TNBC) presents a poor prognosis but shows sensitivity to chemotherapy. Research focuses on optimizing current treatments and exploring novel therapies like PARP inhibitors for better patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and HER2 expression.
- TNBC exhibits unique molecular, histological, and clinical features, often leading to a poor prognosis.
- TNBC shows high concordance with basal-like breast cancer (BLBC) identified through gene expression profiling.
Purpose of the Study:
- To summarize current therapeutic strategies and ongoing research for improving outcomes in TNBC.
- To highlight the heterogeneity within TNBC and BLBC, impacting treatment efficacy.
- To explore novel therapeutic agents and treatment optimization for TNBC patients.
Main Methods:
- Review of existing literature on TNBC and BLBC classification.
- Analysis of gene expression data to define BLBC subtypes.
- Examination of ongoing clinical trials and preclinical research for novel TNBC therapies.
Main Results:
- TNBC and BLBC are heterogeneous, contributing to incomplete concordance and varied clinical behavior.
- Despite sensitivity to chemotherapy, TNBC has an unfavorable prognosis.
- Emerging therapies include PARP inhibitors, EGFR inhibitors, multikinase inhibitors, and antiangiogenic agents.
Conclusions:
- Optimizing current chemotherapy regimens (e.g., platinum salts, dose intensification) is crucial.
- Novel targeted therapies offer promising avenues for improving TNBC patient survival.
- Further research into TNBC heterogeneity is essential for personalized treatment approaches.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...